KRON Projected Dividend Yield
Kronos Bio Inc ( NASDAQ : KRON )Kronos Bio is a late-stage clinical development biopharmaceutical company, with a focus on developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. Co.'s primary product candidate, entospletinib, is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor. Co. is also developing lanraplenib, its orally-administered SYK inhibitor. In addition, Co. is developing KB-0742, its internally discovered, oral cyclin dependent kinase 9 inhibitor, for the treatment of MYC-amplified and other transcriptionally addicted solid tumors. 20 YEAR PERFORMANCE RESULTS |
KRON Dividend History Detail KRON Dividend News KRON Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |